CGS 19755: a novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist with anticonvulsant, anxiolytic and anti-ischemic properties.
CGS 19755 is a potent and selective competitive antagonist at NMDA receptors in the brain. In preclinical animal tests, the compound produces anticonvulsant, anxiolytic and anti-ischemic effects. CGS 19755 is not very active when administered orally, and intravenous administration is the most practical for clinical application. The anti-ischemic potential of CGS 19755 provides the most attractive application for clinical investigation.
Bennett
D A
DA
Research Department, CIBA-Geigy Corporation, Summit, NJ 07901.
Lehmann
J
J
Bernard
P S
PS
Liebman
J M
JM
Williams
M
M
Wood
P L
PL
Boast
C A
CA
Hutchison
A J
AJ
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000927:Anticonvulsants / Q000494:pharmacology; D001667:Binding, Competitive; D007511:Ischemia / Q000188:drug therapy; D010875:Pipecolic Acids / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D010875:Pipecolic Acids; D016194:Receptors, N-Methyl-D-Aspartate; C053672:selfotel